Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patients with Episodic Migraine for the Determination of Molecular and Clinical Biomarkers (MAMBO II Study).
Key facts
- Where
- Barcelona, SpanyolországSee the site
- Phase
- 4. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Spanyolország
- Hospital Universitari Vall d'HebronBarcelona, SpanyolországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
- Trial code
- EU 2024-519770-38-00
- Record updated
- 2026. június 5.
- Original description
- Temporal Evolution of Biochemical Marker Levels in Blood During NTG-Induced Migraine Attacks and After Treatment with Sumatriptan and Rimegepant - Correlation of Biochemical Marker Profiles with Acute Treatment Response to Sumatriptan and Rimegepant During NTG-Induced Migraine Attacks.Read full original descriptionShow less
- Temporal Evolution of Biochemical Marker Levels in Blood During NTG-Induced Migraine Attacks and After Treatment with Sumatriptan and Rimegepant - Correlation of Biochemical Marker Profiles with Acute Treatment Response to Sumatriptan and Rimegepant During NTG-Induced Migraine Attacks.
Inclusion: Adults between 18 and 60 years old; Diagnosis of migraine, with or without aura, according to the The International Classification of Headache Disorders 3rd edition; According to the calendar, frequency of cefalea < 10 days/month; Signature of the Inform Consent Form.
Exclusion: History of poor tolerance or prior hypersensitivity reaction to triptans or gepants; History of severe or refractory migraine attacks unresponsive to treatment with triptans, gepants, or NSAIDs; Preventive treatment for migraines (includes antidepressants, beta-blockers, lisinopril or candesartan, topiramate, valproic acid, botulinum toxin, or CGRP-targeted therapies); Tretament with drugs acting on the central nervous system; Relevant medical or psychiatric diseases; History of unstable ischemic heart disease, cerebrovascular disease, peripheral vasculopathy; History of significant hepatic disease; Contraindication to nitroglycerin; Child-bearing women that not use one acceptable method of birth contro; Pregnant women.